In its January 2026 6-K filing, Sinovac Biotech announced that the Nasdaq Hearings Panel granted continued listing, a critical validation following prior regulatory scrutiny. Sinovac operates through majority-owned subsidiaries focused on vaccines, including live attenuated varieties, and is expanding manufacturing via joint ventures in emerging markets. Governance challenges persist, notably legal disputes over shareholder agreements under Antigua law, which could influence corporate control. The company’s strategic growth hinges on pipeline development and global footprint expansion supported by established regulatory approvals, including WHO prequalification for some products. Financially, despite operating losses, Sinovac maintains solid liquidity with over $335 million cash and manageable net debt as of year-end 2024.